ORMP - Shares of Oramed Pharmaceuticals Inc. (ORMP) Rise to a New 52-Week High

Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) traded today at $20.37, eclipsing its 52-week high. This new high was reached on below average trading volume as 251,000 shares traded hands, while the average 30-day volume is approximately 784,000 shares.

Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) is currently priced 22.8% above its average consensus analyst price target of $15.37.

In the past 52 weeks, Oramed Pharmaceuticals Inc. share prices are bracketed by a low of $2.40 and a high of $20.37 and is now at $19.90, 729% above that low price.

Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer